The role of taxanes in the management of bladder cancer

Oncologist

Volumn 10, Issue 10, 2005, Pages 792-798

  Galsky, Matthew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Chemotherapy; Docetaxel; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CYSTECTOMY; DEATH; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LUNG TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CLINICAL TRIALS, PHASE II; DEOXYCYTIDINE; HUMANS; IFOSFAMIDE; PACLITAXEL; TAXOIDS; URINARY BLADDER NEOPLASMS;

EID: 31444453665     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-10-792     Document Type: Review

References (42)

1. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403-407.
2. Dreicer R, Gustin DM, See WA et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996;156:1606-1608.
3. Papamichael D, Gallagher CJ, Oliver RT et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75:606-607.
4. Roth BJ, Dreicer R, Einhorn LH et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-2270.
5. Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20:937-940.
6. de Wit R, Kruit WH, Stoter G et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998;78:1342-1345.
7. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:1853-1857.
8. Dreicer R, Manola J, Roth BJ et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2000;18:1058-1061.
9. Burch PA, Richardson RL, Cha SS et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 2000;164:1538-1542.
10. Garcia del Muro X, Marcuello E, Guma J et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002;86:326-330.
11. Sengelov L, Kamby C, Lund B et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998;16:3392-3397.
12. Dimopoulos MA, Bakoyannis C, Georgoulias V et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999;10:1385-1388.
13. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004;22:220-228.
14. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-3181.
15. Vaughn DJ, Malkowicz SB, Zoltick B et al. Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium. Semin Oncol 1997;24(suppl 2):S2-47-S2-50.
16. Small EJ, Lew D, Redman BG et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 2000;18:2537-2544.
17. Redman BG, Smith DC, Flaherty L et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998;16:1844-1848.
18. Zielinski CC, Schnack B, Grbovic M et al. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br J Cancer 1998;78:370-374.
19. Vaughn DJ, Malkowicz SB, Zoltick B et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998;16:255-260.
20. Pycha A, Grbovic M, Posch B et al. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology 1999;53:510-515.
21. Vaughn DJ, Manola J, Dreicer R et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 2002;95:1022-1027.
22. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 2004;100:1639-1645.
23. Sweeney CJ, Williams SD, Finch DE et al. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 1999;86:514-518.
24. Meluch AA, Greco FA, Burris HA 3rd et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001;19:3018-3024.
25. Sternberg CN, Calabro F, Pizzocaro G et al. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92:2993-2998.
26. Li J, Juliar B, Yiannoutsos C et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005;23:1185-1191.
27. Dreicer R, Manola J, Schneider DJ et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97:2743-2747.
28. Bajorin DF, McCaffrey JA, Hilton S et al. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J Clin Oncol 1998;16:2722-2727.
29. Bajorin DF, McCaffrey JA, Dodd PM et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000;88:1671-1678.
30. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000;18:3247-3255.
31. Hussain M, Vaishampayan U, Du W et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:2527-2533.
32. Geller NL, Sternberg CN, Penenberg D et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67:1525-1531.
33. Loehrer PJ Sr., Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-1073.
34. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-2569.
35. Bellmunt J, Albanell J, Paz-Ares L et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002;95:751-757.
36. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169.
37. Dodd PM, McCaffrey JA, Hilton S et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 2000;18:840-846.
38. Maluf F, Hilton S, Nanus D et al. Sequential doxorubicin/gemcitabine (AG) and ifosfamide, paclitaxel, and cisplatin (ITP) chemotherapy (AGITP) in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 2000;19:1344a.
39. Advanced Bladder Cancer Meta-Analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-1934.
40. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
41. [No authors listed.] Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999;354:533-540.
42. Bellmunt J, Albanell J, Paz-Ares L et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002;95:751-757.